Aclaris Therapeutics, Inc. (LON:0H8T)
London
· Delayed Price · Currency is GBP · Price in USD 1.135
-0.014 (-1.25%)
At close: Apr 16, 2025
Aclaris Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 24.57 | 39.88 | 45.28 | 27.35 | 22.06 | Upgrade
|
| Short-Term Investments | 89.02 | 79.23 | 172.29 | 164.07 | 32.07 | Upgrade
|
| Cash & Short-Term Investments | 113.59 | 119.11 | 217.57 | 191.41 | 54.13 | Upgrade
|
| Cash Growth | -4.63% | -45.26% | 13.66% | 253.61% | -26.12% | Upgrade
|
| Receivables | 8.92 | 0.3 | 0.48 | 0.62 | 0.77 | Upgrade
|
| Prepaid Expenses | 3.44 | 9.45 | 13.5 | 13 | 2.59 | Upgrade
|
| Total Current Assets | 125.95 | 128.86 | 231.55 | 205.03 | 57.49 | Upgrade
|
| Property, Plant & Equipment | 3.85 | 5.48 | 3.78 | 4.77 | 5.78 | Upgrade
|
| Long-Term Investments | 90.3 | 62.77 | 12.24 | 34.24 | - | Upgrade
|
| Other Intangible Assets | - | - | 6.97 | 7.05 | 7.12 | Upgrade
|
| Other Long-Term Assets | 0.22 | 0.3 | 0.05 | 0.12 | 0.39 | Upgrade
|
| Total Assets | 220.33 | 197.41 | 254.6 | 251.21 | 70.78 | Upgrade
|
| Accounts Payable | 4.69 | 8.88 | 10.35 | 9.99 | 5.25 | Upgrade
|
| Accrued Expenses | 7.6 | 10.86 | 8.2 | 7.37 | 5.91 | Upgrade
|
| Current Portion of Leases | 0.48 | 0.43 | 0.68 | 0.72 | 0.6 | Upgrade
|
| Current Unearned Revenue | 3.89 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 14.94 | 10.79 | 2.7 | 4.85 | 3.11 | Upgrade
|
| Total Current Liabilities | 31.6 | 30.95 | 21.94 | 22.93 | 14.87 | Upgrade
|
| Long-Term Debt | - | - | - | - | 10.65 | Upgrade
|
| Long-Term Leases | 2.12 | 3.07 | 1.57 | 2.17 | 2.89 | Upgrade
|
| Long-Term Unearned Revenue | 20.04 | - | - | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 0.37 | 0.37 | 0.37 | Upgrade
|
| Other Long-Term Liabilities | 11.02 | 6.2 | 33.1 | 28.4 | 4.35 | Upgrade
|
| Total Liabilities | 64.77 | 40.23 | 56.98 | 53.87 | 33.13 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 1,058 | 928.08 | 880.83 | 792.97 | 542.29 | Upgrade
|
| Retained Earnings | -902.86 | -770.8 | -682.32 | -595.41 | -504.54 | Upgrade
|
| Comprehensive Income & Other | 0.1 | -0.11 | -0.9 | -0.22 | -0.09 | Upgrade
|
| Total Common Equity | 155.55 | 157.18 | 197.62 | 197.34 | 37.65 | Upgrade
|
| Shareholders' Equity | 155.55 | 157.18 | 197.62 | 197.34 | 37.65 | Upgrade
|
| Total Liabilities & Equity | 220.33 | 197.41 | 254.6 | 251.21 | 70.78 | Upgrade
|
| Total Debt | 2.6 | 3.5 | 2.25 | 2.89 | 14.15 | Upgrade
|
| Net Cash (Debt) | 201.3 | 178.38 | 227.56 | 222.76 | 39.98 | Upgrade
|
| Net Cash Growth | 12.85% | -21.61% | 2.15% | 457.17% | -42.11% | Upgrade
|
| Net Cash Per Share | 2.60 | 2.56 | 3.49 | 3.93 | 0.94 | Upgrade
|
| Filing Date Shares Outstanding | 107.92 | 70.93 | 66.69 | 61.28 | 51.8 | Upgrade
|
| Total Common Shares Outstanding | 107.85 | 70.89 | 66.69 | 61.23 | 45.11 | Upgrade
|
| Working Capital | 94.36 | 97.9 | 209.61 | 182.1 | 42.62 | Upgrade
|
| Book Value Per Share | 1.44 | 2.22 | 2.96 | 3.22 | 0.83 | Upgrade
|
| Tangible Book Value | 155.55 | 157.18 | 190.65 | 190.29 | 30.53 | Upgrade
|
| Tangible Book Value Per Share | 1.44 | 2.22 | 2.86 | 3.11 | 0.68 | Upgrade
|
| Machinery | 5 | 4.97 | 4.01 | 3.61 | 3.15 | Upgrade
|
| Leasehold Improvements | 0.82 | 0.82 | 1.12 | 1.12 | 1.12 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.